Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Open-labeled, 1 Year Extension Study of the Efficacy and the Safety During Treatment of Tocilizumab in Patients With Active RA Completing Treatment CWP-TCZ301 Study

NCT01256736 is registered in ClinicalTrials.gov with JW Pharmaceutical as lead sponsor.

NCT NCT01256736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01256736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Open-labeled, 1 Year Extension Study of the Efficacy and the Safety During Treatment of Tocilizumab in Patients With Active RA Completing Treatment CWP-TCZ301 Study
Lead sponsor
JW Pharmaceutical
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2010
Completion date
November 30, 2013
Enrollment
89 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis